Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• P-glycoprotein (P-gp) at the blood-brain barrier enhances antiepileptic drug efflux, contributing to epilepsy pharmacoresistance.
• Seizure activity can lead to P-gp overexpression, further exacerbating drug resistance.

Purpose of the Study:

• To review strategies for blocking P-gp upregulation to improve antiepileptic drug brain penetration and efficacy.
• To discuss therapeutic targets involved in seizure-associated P-gp transcriptional activation.

Main Methods:

• Evaluation of signaling factors such as N-methyl-d-aspartate (NMDA) receptor, cyclooxygenase-2, and prostaglandin E2 EP1 receptor in rodent models.
• Comparison of P-gp upregulation blocking strategies with alternative methods for overcoming transporter-associated resistance.

Main Results:

• Targeting specific signaling factors effectively controls P-gp expression in rodent models.
• Interventions improved antiepileptic drug brain penetration and helped overcome pharmacoresistance.
• Blocking P-gp upregulation preserves basal transporter function, offering advantages over direct transporter inhibition.

Conclusions:

• Strategies targeting signaling pathways offer a promising approach to combat epilepsy pharmacoresistance.
• Further research is needed to define the clinical relevance of transporter overexpression and develop patient-specific evaluation tools.